370 related articles for article (PubMed ID: 20497550)
1. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
[TBL] [Abstract][Full Text] [Related]
2. The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.
Tyler C; Kapur A; Felder M; Belisle JA; Trautman C; Gubbels JA; Connor JP; Patankar MS
Am J Reprod Immunol; 2012 Jul; 68(1):28-37. PubMed ID: 22380506
[TBL] [Abstract][Full Text] [Related]
3. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
5. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
6. MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.
Wu Y; Liu Q; Xie Y; Zhu J; Zhang S; Ge Y; Guo J; Luo N; Huang W; Xu R; Liu S; Cheng Z
J Ovarian Res; 2023 Aug; 16(1):181. PubMed ID: 37644468
[TBL] [Abstract][Full Text] [Related]
7. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
8. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
[TBL] [Abstract][Full Text] [Related]
9. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells.
Adeniji OS; Kuri-Cervantes L; Yu C; Xu Z; Ho M; Chew GM; Shikuma C; Tomescu C; George AF; Roan NR; Ndhlovu LC; Liu Q; Muthumani K; Weiner DB; Betts MR; Xiao H; Abdel-Mohsen M
PLoS Pathog; 2021 Nov; 17(11):e1010034. PubMed ID: 34762717
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
Ikehara Y; Ikehara SK; Paulson JC
J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes.
Nicoll G; Ni J; Liu D; Klenerman P; Munday J; Dubock S; Mattei MG; Crocker PR
J Biol Chem; 1999 Nov; 274(48):34089-95. PubMed ID: 10567377
[TBL] [Abstract][Full Text] [Related]
13. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
14. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.
Yoshimura A; Asahina Y; Chang LY; Angata T; Tanaka H; Kitajima K; Sato C
J Biol Chem; 2021; 296():100477. PubMed ID: 33640457
[TBL] [Abstract][Full Text] [Related]
16. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
17. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
Mitic N; Milutinovic B; Jankovic M
Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
[TBL] [Abstract][Full Text] [Related]
18. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
[TBL] [Abstract][Full Text] [Related]
19. Increased Frequency of Dysfunctional Siglec-7
Sakamoto Y; Yoshio S; Doi H; Mori T; Matsuda M; Kawai H; Shimagaki T; Yoshikawa S; Aoki Y; Osawa Y; Yoshida Y; Arai T; Itokawa N; Atsukawa M; Ito T; Honda T; Mise Y; Ono Y; Takahashi Y; Saiura A; Taketomi A; Kanto T
Front Immunol; 2021; 12():603133. PubMed ID: 33692781
[TBL] [Abstract][Full Text] [Related]
20. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
